4-EA-NBOMe

4-EA-NBOMe
Legal status
Legal status	UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name 1-(4-ethylphenyl)-N-[(2-methoxyphenyl)methyl]propan-2-amine;
PubChem CID	132280994;
CompTox Dashboard (EPA)	DTXSID301337102 ;
Chemical and physical data
Formula	C19H25NO
Molar mass	283.415 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CC=C(C=C1)CC(C)NCC2=CC=CC=C2OC;
	InChI InChI=1S/C19H25NO/c1-4-16-9-11-17(12-10-16)13-15(2)20-14-18-7-5-6-8-19(18)21-3/h5-12,15,20H,4,13-14H2,1-3H3; Key:WWWBFWRUWWKJIJ-UHFFFAOYSA-N;

4-EA-NBOMe is a substituted amphetamine and 25-NB derivative which has been sold as a designer drug. It was first identified by a forensic laboratory in Germany in 2014,^[1] but while its analytical properties and metabolism have been studied,^[2]^[3]^[4] its pharmacology remains unknown.

References

^ "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2015.
^ Westphal F, Girreser U, Waldmüller D (September 2016). "Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs". Drug Testing and Analysis. 8 (9): 910–9. doi:10.1002/dta.1889. PMID 26606897.
^ Caspar AT, Westphal F, Meyer MR, Maurer HH (January 2018). "LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques". Analytical and Bioanalytical Chemistry. 410 (3): 897–912. doi:10.1007/s00216-017-0526-0. PMID 28762065. S2CID 206923339.
^ Caspar AT, Meyer MR, Maurer HH (March 2018). "Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach". Toxicology Letters. 285: 1–8. doi:10.1016/j.toxlet.2017.12.017. PMID 29277574.

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

[1] "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2015.

[pmid26606897-2] Westphal F, Girreser U, Waldmüller D (September 2016). "Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs". Drug Testing and Analysis. 8 (9): 910–9. doi:10.1002/dta.1889. PMID 26606897.

[pmid28762065-3] Caspar AT, Westphal F, Meyer MR, Maurer HH (January 2018). "LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques". Analytical and Bioanalytical Chemistry. 410 (3): 897–912. doi:10.1007/s00216-017-0526-0. PMID 28762065. S2CID 206923339.

[pmid29277574-4] Caspar AT, Meyer MR, Maurer HH (March 2018). "Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach". Toxicology Letters. 285: 1–8. doi:10.1016/j.toxlet.2017.12.017. PMID 29277574.

[1]

[2]

[3]

[4]

See also

References